"FDA Grants Full Approval to Lecanemab: A Promising Breakthrough in Alzheimer's Treatment"

The U.S. Food and Drug Administration (FDA) has granted full approval to lecanemab (Leqembi), the first drug proven to slow the progression of Alzheimer's disease. Lecanemab works by reducing amyloid plaques in the brain, a hallmark of Alzheimer's. A phase 3 clinical trial showed that lecanemab reduced cognitive and functional decline in patients by 27% and cleared more amyloid plaques after 18 months of treatment. However, the drug comes with risks of bleeding and brain swelling. Medicare and Medicaid will cover lecanemab, making it potentially affordable for many. This approval marks a significant milestone in Alzheimer's treatment, but patients should have a careful discussion with their doctors about the risks and benefits.